Q1 · MEDICINE
Article
Author: Graf, Michael ; Roerden, Malte ; Walz, Juliane S ; Fehr, Michael ; Rabsteyn, Armin ; Karbach, Julia ; Rothbauer, Ulrich ; Gouttefangeas, Cécile ; Kohlbacher, Oliver ; Schneiderhan-Marra, Nicole ; Rammensee, Hans-Georg ; Bakchoul, Tamam ; Bilich, Tatjana ; Stevanović, Stefan ; Peter, Andreas ; Bauer, Jens ; Hörber, Sebastian ; Traenkle, Bjoern ; Kowalewski, Daniel J ; Hagelstein, Ilona ; Templin, Markus F ; Lübke, Maren ; Rieth, Jonas ; Märklin, Melanie ; Kaiser, Philipp D ; Wacker, Marcel ; Heitmann, Jonas S ; Preuß, Beate ; Strengert, Monika ; Mirakaj, Valbona ; Krause, Gérard ; Gruber, Lena-Christin ; Nelde, Annika ; Stos-Zweifel, Vlatka ; Klein, Reinhild ; Maringer, Yacine ; Salih, Helmut R ; Rachfalski, David ; Junker, Daniel ; Joos, Thomas O ; Becker, Matthias ; Jäger, Elke
T cell immunity is central for the control of viral infections. To characterize T cell immunity, but also for the development of vaccines, identification of exact viral T cell epitopes is fundamental. Here we identify and characterize multiple dominant and subdominant SARS-CoV-2 HLA class I and HLA-DR peptides as potential T cell epitopes in COVID-19 convalescent and unexposed individuals. SARS-CoV-2-specific peptides enabled detection of post-infectious T cell immunity, even in seronegative convalescent individuals. Cross-reactive SARS-CoV-2 peptides revealed pre-existing T cell responses in 81% of unexposed individuals and validated similarity with common cold coronaviruses, providing a functional basis for heterologous immunity in SARS-CoV-2 infection. Diversity of SARS-CoV-2 T cell responses was associated with mild symptoms of COVID-19, providing evidence that immunity requires recognition of multiple epitopes. Together, the proposed SARS-CoV-2 T cell epitopes enable identification of heterologous and post-infectious T cell immunity and facilitate development of diagnostic, preventive and therapeutic measures for COVID-19.